NEW YORK, Feb. 10 (GenomeWeb News) - Serenex today said it has signed an evaluation agreement for its chemoproteomics technology with Aventis.

Aventis Pharmaceuticals, the Bridgewater, NJ-based subsidiary of Strasbourg, France-based Aventis, will "evaluate the utility" of Serenex's Proteome Mining and Functional Proteome Fractionation profiling technologies, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.